Bioavailability of long-chain omega-3 fatty acids
Abstract Supplements have reached a prominent role in improving the supply of long-chain omega-3 fatty acids, such as Eicosapentaenoic acid (EPA 20:5 n −3) and Docosahexaenoic acid (DHA 22:6 n −3). Similar to other nutrients, the availability of omega-3 fatty acids is highly variable and determined...
Gespeichert in:
| Veröffentlicht in: | Prostaglandins, leukotrienes and essential fatty acids leukotrienes and essential fatty acids, 2013-07, Vol.89 (1), p.1-8 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Prostaglandins, leukotrienes and essential fatty acids |
| container_volume | 89 |
| creator | Schuchardt, Jan Philipp Hahn, Andreas |
| description | Abstract Supplements have reached a prominent role in improving the supply of long-chain omega-3 fatty acids, such as Eicosapentaenoic acid (EPA 20:5 n −3) and Docosahexaenoic acid (DHA 22:6 n −3). Similar to other nutrients, the availability of omega-3 fatty acids is highly variable and determined by numerous factors. However, the question of omega-3 fatty acids bioavailability has long been disregarded, which may have contributed to the neutral or negative results concerning their effects in several studies. This review provides an overview of the influence of chemical binding form (free fatty acids bound in ethylesters, triacylglycerides or phospholipids), matrix effects (capsule ingestion with concomitant intake of food, fat content in food) or galenic form (i.e. microencapsulation, emulsification) on the bioavailability of omega-3 fatty acids. There is a need to systematically investigate the bioavailability of omega-3 fatty acids formulations, which might be a key to designing more effective studies in the future. |
| doi_str_mv | 10.1016/j.plefa.2013.03.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1367880311</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0952327813000719</els_id><sourcerecordid>1367880311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-4a50492a3e057fac1f58db8606e8edc90f99a7cc422b537e37f24053b44107573</originalsourceid><addsrcrecordid>eNqFkU1LxDAQhoMoun78AkH26KXrTNI27UFBxS8QPKjnkKYTzZpt1qYr7L8366oHL8LAHOZ9Z5jnZewQYYKA5cl0Mvdk9YQDigmkQthgIywEz3jFxSYbQV3wTHBZ7bDdGKcAwBHzbbbDRSlLwfmI4YUL-kM7rxvn3bAcBzv2oXvJzKt23TjM6EVnYmz1kGbauDbusy2rfaSD777Hnq-vni5vs_uHm7vL8_vM5BUMWa4LyGuuBUEhrTZoi6ptqhJKqqg1Ndi61tKYnPOmEJKEtDyHQjR5jiALKfbY8XrvvA_vC4qDmrloyHvdUVhEhemHqgKBmKRiLTV9iLEnq-a9m-l-qRDUipWaqi9WasVKQSqE5Dr6PrBoZtT-en7gJMHpWkDpzQ9HvYrGUWeodT2ZQbXB_XPg7I_feNc5o_0bLSlOw6LvEkGFKnIF6nEV1yotFCkpibX4BFPYjZ4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1367880311</pqid></control><display><type>article</type><title>Bioavailability of long-chain omega-3 fatty acids</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Schuchardt, Jan Philipp ; Hahn, Andreas</creator><creatorcontrib>Schuchardt, Jan Philipp ; Hahn, Andreas</creatorcontrib><description>Abstract Supplements have reached a prominent role in improving the supply of long-chain omega-3 fatty acids, such as Eicosapentaenoic acid (EPA 20:5 n −3) and Docosahexaenoic acid (DHA 22:6 n −3). Similar to other nutrients, the availability of omega-3 fatty acids is highly variable and determined by numerous factors. However, the question of omega-3 fatty acids bioavailability has long been disregarded, which may have contributed to the neutral or negative results concerning their effects in several studies. This review provides an overview of the influence of chemical binding form (free fatty acids bound in ethylesters, triacylglycerides or phospholipids), matrix effects (capsule ingestion with concomitant intake of food, fat content in food) or galenic form (i.e. microencapsulation, emulsification) on the bioavailability of omega-3 fatty acids. There is a need to systematically investigate the bioavailability of omega-3 fatty acids formulations, which might be a key to designing more effective studies in the future.</description><identifier>ISSN: 0952-3278</identifier><identifier>EISSN: 1532-2823</identifier><identifier>DOI: 10.1016/j.plefa.2013.03.010</identifier><identifier>PMID: 23676322</identifier><language>eng</language><publisher>Scotland: Elsevier Ltd</publisher><subject>Advanced Basic Science ; Biological Availability ; DHA ; Dietary Supplements ; Docosahexaenoic Acids - administration & dosage ; Docosahexaenoic Acids - metabolism ; Eicosapentaenoic Acid - administration & dosage ; Eicosapentaenoic Acid - metabolism ; Emulsification ; Endocrinology & Metabolism ; EPA ; Ethyl-ester ; Fatty Acids, Omega-3 - administration & dosage ; Fatty Acids, Omega-3 - metabolism ; Formulation ; Humans ; Microencapsulation ; Models, Biological ; Omega-3 index ; PUFA ; Re-esterified triglycerides ; Supplementation</subject><ispartof>Prostaglandins, leukotrienes and essential fatty acids, 2013-07, Vol.89 (1), p.1-8</ispartof><rights>Elsevier Ltd</rights><rights>2013 Elsevier Ltd</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-4a50492a3e057fac1f58db8606e8edc90f99a7cc422b537e37f24053b44107573</citedby><cites>FETCH-LOGICAL-c480t-4a50492a3e057fac1f58db8606e8edc90f99a7cc422b537e37f24053b44107573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.plefa.2013.03.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23676322$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schuchardt, Jan Philipp</creatorcontrib><creatorcontrib>Hahn, Andreas</creatorcontrib><title>Bioavailability of long-chain omega-3 fatty acids</title><title>Prostaglandins, leukotrienes and essential fatty acids</title><addtitle>Prostaglandins Leukot Essent Fatty Acids</addtitle><description>Abstract Supplements have reached a prominent role in improving the supply of long-chain omega-3 fatty acids, such as Eicosapentaenoic acid (EPA 20:5 n −3) and Docosahexaenoic acid (DHA 22:6 n −3). Similar to other nutrients, the availability of omega-3 fatty acids is highly variable and determined by numerous factors. However, the question of omega-3 fatty acids bioavailability has long been disregarded, which may have contributed to the neutral or negative results concerning their effects in several studies. This review provides an overview of the influence of chemical binding form (free fatty acids bound in ethylesters, triacylglycerides or phospholipids), matrix effects (capsule ingestion with concomitant intake of food, fat content in food) or galenic form (i.e. microencapsulation, emulsification) on the bioavailability of omega-3 fatty acids. There is a need to systematically investigate the bioavailability of omega-3 fatty acids formulations, which might be a key to designing more effective studies in the future.</description><subject>Advanced Basic Science</subject><subject>Biological Availability</subject><subject>DHA</subject><subject>Dietary Supplements</subject><subject>Docosahexaenoic Acids - administration & dosage</subject><subject>Docosahexaenoic Acids - metabolism</subject><subject>Eicosapentaenoic Acid - administration & dosage</subject><subject>Eicosapentaenoic Acid - metabolism</subject><subject>Emulsification</subject><subject>Endocrinology & Metabolism</subject><subject>EPA</subject><subject>Ethyl-ester</subject><subject>Fatty Acids, Omega-3 - administration & dosage</subject><subject>Fatty Acids, Omega-3 - metabolism</subject><subject>Formulation</subject><subject>Humans</subject><subject>Microencapsulation</subject><subject>Models, Biological</subject><subject>Omega-3 index</subject><subject>PUFA</subject><subject>Re-esterified triglycerides</subject><subject>Supplementation</subject><issn>0952-3278</issn><issn>1532-2823</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1LxDAQhoMoun78AkH26KXrTNI27UFBxS8QPKjnkKYTzZpt1qYr7L8366oHL8LAHOZ9Z5jnZewQYYKA5cl0Mvdk9YQDigmkQthgIywEz3jFxSYbQV3wTHBZ7bDdGKcAwBHzbbbDRSlLwfmI4YUL-kM7rxvn3bAcBzv2oXvJzKt23TjM6EVnYmz1kGbauDbusy2rfaSD777Hnq-vni5vs_uHm7vL8_vM5BUMWa4LyGuuBUEhrTZoi6ptqhJKqqg1Ndi61tKYnPOmEJKEtDyHQjR5jiALKfbY8XrvvA_vC4qDmrloyHvdUVhEhemHqgKBmKRiLTV9iLEnq-a9m-l-qRDUipWaqi9WasVKQSqE5Dr6PrBoZtT-en7gJMHpWkDpzQ9HvYrGUWeodT2ZQbXB_XPg7I_feNc5o_0bLSlOw6LvEkGFKnIF6nEV1yotFCkpibX4BFPYjZ4</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>Schuchardt, Jan Philipp</creator><creator>Hahn, Andreas</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130701</creationdate><title>Bioavailability of long-chain omega-3 fatty acids</title><author>Schuchardt, Jan Philipp ; Hahn, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-4a50492a3e057fac1f58db8606e8edc90f99a7cc422b537e37f24053b44107573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Advanced Basic Science</topic><topic>Biological Availability</topic><topic>DHA</topic><topic>Dietary Supplements</topic><topic>Docosahexaenoic Acids - administration & dosage</topic><topic>Docosahexaenoic Acids - metabolism</topic><topic>Eicosapentaenoic Acid - administration & dosage</topic><topic>Eicosapentaenoic Acid - metabolism</topic><topic>Emulsification</topic><topic>Endocrinology & Metabolism</topic><topic>EPA</topic><topic>Ethyl-ester</topic><topic>Fatty Acids, Omega-3 - administration & dosage</topic><topic>Fatty Acids, Omega-3 - metabolism</topic><topic>Formulation</topic><topic>Humans</topic><topic>Microencapsulation</topic><topic>Models, Biological</topic><topic>Omega-3 index</topic><topic>PUFA</topic><topic>Re-esterified triglycerides</topic><topic>Supplementation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schuchardt, Jan Philipp</creatorcontrib><creatorcontrib>Hahn, Andreas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Prostaglandins, leukotrienes and essential fatty acids</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schuchardt, Jan Philipp</au><au>Hahn, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bioavailability of long-chain omega-3 fatty acids</atitle><jtitle>Prostaglandins, leukotrienes and essential fatty acids</jtitle><addtitle>Prostaglandins Leukot Essent Fatty Acids</addtitle><date>2013-07-01</date><risdate>2013</risdate><volume>89</volume><issue>1</issue><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>0952-3278</issn><eissn>1532-2823</eissn><abstract>Abstract Supplements have reached a prominent role in improving the supply of long-chain omega-3 fatty acids, such as Eicosapentaenoic acid (EPA 20:5 n −3) and Docosahexaenoic acid (DHA 22:6 n −3). Similar to other nutrients, the availability of omega-3 fatty acids is highly variable and determined by numerous factors. However, the question of omega-3 fatty acids bioavailability has long been disregarded, which may have contributed to the neutral or negative results concerning their effects in several studies. This review provides an overview of the influence of chemical binding form (free fatty acids bound in ethylesters, triacylglycerides or phospholipids), matrix effects (capsule ingestion with concomitant intake of food, fat content in food) or galenic form (i.e. microencapsulation, emulsification) on the bioavailability of omega-3 fatty acids. There is a need to systematically investigate the bioavailability of omega-3 fatty acids formulations, which might be a key to designing more effective studies in the future.</abstract><cop>Scotland</cop><pub>Elsevier Ltd</pub><pmid>23676322</pmid><doi>10.1016/j.plefa.2013.03.010</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0952-3278 |
| ispartof | Prostaglandins, leukotrienes and essential fatty acids, 2013-07, Vol.89 (1), p.1-8 |
| issn | 0952-3278 1532-2823 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1367880311 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Advanced Basic Science Biological Availability DHA Dietary Supplements Docosahexaenoic Acids - administration & dosage Docosahexaenoic Acids - metabolism Eicosapentaenoic Acid - administration & dosage Eicosapentaenoic Acid - metabolism Emulsification Endocrinology & Metabolism EPA Ethyl-ester Fatty Acids, Omega-3 - administration & dosage Fatty Acids, Omega-3 - metabolism Formulation Humans Microencapsulation Models, Biological Omega-3 index PUFA Re-esterified triglycerides Supplementation |
| title | Bioavailability of long-chain omega-3 fatty acids |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T03%3A35%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bioavailability%20of%20long-chain%20omega-3%20fatty%20acids&rft.jtitle=Prostaglandins,%20leukotrienes%20and%20essential%20fatty%20acids&rft.au=Schuchardt,%20Jan%20Philipp&rft.date=2013-07-01&rft.volume=89&rft.issue=1&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=0952-3278&rft.eissn=1532-2823&rft_id=info:doi/10.1016/j.plefa.2013.03.010&rft_dat=%3Cproquest_cross%3E1367880311%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1367880311&rft_id=info:pmid/23676322&rft_els_id=S0952327813000719&rfr_iscdi=true |